ATE421321T1 - Methoden zur behandlung von angstzuständen - Google Patents

Methoden zur behandlung von angstzuständen

Info

Publication number
ATE421321T1
ATE421321T1 AT01991398T AT01991398T ATE421321T1 AT E421321 T1 ATE421321 T1 AT E421321T1 AT 01991398 T AT01991398 T AT 01991398T AT 01991398 T AT01991398 T AT 01991398T AT E421321 T1 ATE421321 T1 AT E421321T1
Authority
AT
Austria
Prior art keywords
alkyl
radical
methods
anxiety
pharmaceutically acceptable
Prior art date
Application number
AT01991398T
Other languages
English (en)
Inventor
Mark Bowlby
Sharon Rosenzweig-Lipson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE421321T1 publication Critical patent/ATE421321T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01991398T 2000-12-20 2001-12-19 Methoden zur behandlung von angstzuständen ATE421321T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25683400P 2000-12-20 2000-12-20

Publications (1)

Publication Number Publication Date
ATE421321T1 true ATE421321T1 (de) 2009-02-15

Family

ID=22973775

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01991398T ATE421321T1 (de) 2000-12-20 2001-12-19 Methoden zur behandlung von angstzuständen

Country Status (9)

Country Link
US (1) US6589986B2 (de)
EP (1) EP1343495B1 (de)
JP (1) JP2004518653A (de)
AT (1) ATE421321T1 (de)
AU (1) AU2002231122A1 (de)
CA (1) CA2431278A1 (de)
DE (1) DE60137540D1 (de)
MX (1) MXPA03005497A (de)
WO (1) WO2002049628A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183395A1 (en) * 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
CN100448867C (zh) * 2002-12-27 2009-01-07 H·隆德贝克有限公司 用于治疗中枢神经系统疾病的1,2,4-三氨基苯衍生物
ES2282701T3 (es) * 2002-12-27 2007-10-16 H. Lundbeck A/S Derivados de 1,2,4-triaminobenceno utiles para tratar trastornos del sistema nervioso central.
WO2004082677A1 (en) * 2003-03-21 2004-09-30 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
MXPA05010174A (es) * 2003-04-25 2005-11-08 Lundbeck & Co As H Derivados de indol e indolina sustituidos.
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
EP1861394A1 (de) 2005-03-03 2007-12-05 H.Lundbeck A/S Substituierte pyridinderivate
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
SG174095A1 (en) * 2006-08-23 2011-09-29 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CN101578259A (zh) * 2006-11-28 2009-11-11 威朗国际制药公司 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
CN101868443A (zh) * 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-苯基邻氨基苯甲酸衍生物及其用途
AU2009270768A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
CN104470893A (zh) * 2012-04-30 2015-03-25 赛弗卢尔生命科学有限责任公司 氟化2-氨基-4-(苄基氨基)苯基氨基甲酸酯衍生物
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US11358930B2 (en) 2018-04-20 2022-06-14 University of Pittsburgh—of the Commonwealth System of Higher Education Selective potassium channel agonists
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
MX2022005490A (es) 2019-11-08 2022-08-10 Xenon Pharmaceuticals Inc Metodos para el tratamiento de trastornos depresivos.
CA3159876A1 (en) * 2019-12-06 2021-06-10 James MURROUGH Method of treatment with kcnq channel openers
WO2021211867A1 (en) * 2020-04-16 2021-10-21 Attune Neurosciences, Inc. Kv7 modulators for treating sleep or anxiety disorders
US11957675B2 (en) 2021-02-09 2024-04-16 Xenon Pharmaceuticals Inc. Methods and uses for treating anhedonia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
ATE380176T1 (de) 1999-08-04 2007-12-15 Icagen Inc Benzanilide als öffner des kaliumkanals
EP1200086A4 (de) 1999-08-04 2009-05-27 Icagen Inc Methoden zur behandlung oder vorbeugung von schmerzen und angstzuständen
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain

Also Published As

Publication number Publication date
WO2002049628A2 (en) 2002-06-27
EP1343495B1 (de) 2009-01-21
AU2002231122A1 (en) 2002-07-01
US20020111379A1 (en) 2002-08-15
US6589986B2 (en) 2003-07-08
CA2431278A1 (en) 2002-06-27
EP1343495A2 (de) 2003-09-17
JP2004518653A (ja) 2004-06-24
DE60137540D1 (de) 2009-03-12
WO2002049628A3 (en) 2002-10-17
MXPA03005497A (es) 2003-10-06

Similar Documents

Publication Publication Date Title
ATE421321T1 (de) Methoden zur behandlung von angstzuständen
DK0775129T3 (da) 3-Benzoylbenzofuranderivater som thyroidhormonantagonister
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
PE20010964A1 (es) Derivados de tiazolilamida
BR0211078A (pt) Compostos, processo papa a preparação e uso dos mesmos, composições herbicidas, e, método para o controle de ervas daninhas em áreas cultivadas
IL160045A0 (en) Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
YU57603A (sh) Inhibitori fosfodiesteraze 4
UY25143A1 (es) Procedimiento para la preparacion de inhibidores de proteasas.
EP0959906A4 (de)
DE3853577D1 (de) Benzyliden-Malononitril-Derivate zur Hemmung von proliferativen Prozessen in Säugetierzellen.
HRP20090474T1 (hr) Postupak i intermedijeri za sintezu kaspofungina
FI954016A0 (fi) Uudet yhdisteet
EP2289887A3 (de) Epoxidcarboxylsäureamide, Azide und Aminoalkohole sowie Verfahren zur Herstellung von Alpha-Ketoamiden damit
ATE326964T1 (de) Aminosäurederivate zur behandlung der alzheimer- krankheit
DE60210960D1 (de) Carbamat-verbindungen zur prävention oder behandlung von angstzuständen
ATE101040T1 (de) Derivate und analoge von pyrimidon zur behandlung von asthma und bestimmte hautkrankheiten.
BR9606429A (pt) Composto composição e processo para tratamento de disfunção mediada por uPar- ou uPa-
BR0116721A (pt) Processo para a preparação de (±)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperi dina
ATE232202T1 (de) Verfahren zur herstellung von n-(2- (dimethylamino)ethyl)akridin-4-carbonsäureamide
ATE399018T1 (de) Verwendung von s-ä2,3-bispalmitoyloxy-(2rs)- propylücysteinyl-gnndesnisfkek (malp-2)
DE59802149D1 (de) Fungizide mischungen
DE69916577D1 (de) Azetidincarboxamid-derivate zur behandlung von zns störungen
DE69006471D1 (de) Phenylacetonitrilalkylaminoalkyl-(ortho-substituierte)-Arylverbindungen als Immunosupressoren.
WO2002088091A3 (en) Inhibitors of human rhinovirus 2a cysteine protease
ATE270295T1 (de) Benzoxazine zur verwendung in der behandlung parkinsonscher krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties